CN1682703A - Sterilizing gel - Google Patents
Sterilizing gel Download PDFInfo
- Publication number
- CN1682703A CN1682703A CN 200510053904 CN200510053904A CN1682703A CN 1682703 A CN1682703 A CN 1682703A CN 200510053904 CN200510053904 CN 200510053904 CN 200510053904 A CN200510053904 A CN 200510053904A CN 1682703 A CN1682703 A CN 1682703A
- Authority
- CN
- China
- Prior art keywords
- gel
- chlorhexidine
- weight amount
- total formulation
- formulation weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to sterilizing gel, and sterilizing gel containing chlorhexidine or its physiologically acceptable salt as active component. The sterilizing gel contains also stuffing, excipient, synergist and pH regulator.
Description
Technical field
The present invention relates to a kind of sterilizing gel, especially relate to and contain the sterilizing gel that active component is chlorhexidine or its physiologically acceptable salt.
Technical background
Women self physiological environment has particularity, and vagina and vulva portion is warm and moist, is fit to very much the breeding of multiple pathogenic microorganism, causes various gynecological inflammations and abnormal flavour.According to data, 80% adult women will suffer from gynecological inflammation in life one to twice, and wherein the most commonly vaginitis and cervical disease also have chlamydia, mycoplasma infection.Because of clear water can't thoroughly be removed secretions and dirt, so wreaking havoc also of pathogenic microorganism just can hardly be avoided.
Chlorhexidine (hibitane), chemical name 1,6-pair (just-to the chlorobenzene biguanide) hexane, have another name called two chlorobenzene biguanide.Belong to lower toxicity, embarrass absorption of human body, human body skin is not had the obvious stimulation effect.In the working concentration scope, be a kind of desirable disinfectant of nontoxic, non-stimulated and few sensitization as skin, mucosa disinfectant.Chlorhexidine (hibitane) is efficient, wide-spectrum bactericide, can kill Gram-negative and gram-positive bacterium brood body, and Mlc is low, and some fungus and bacterial spore are had bacteriostasis.This medicine with can cause the semi permeability of film to be destroyed rapidly by the absorption of the positive charge on the cell serous coat after antibacterial contacts, the thalline content condenses, and reaches the sterilization purpose.Chlorhexidine (hibitane) is widely used in skin degerming, mucosa sterilization, wound surface sterilization, surface disinfection.Aspect Amino-Cerv, chlorhexidine (hibitane) action range, not only effective to colpitis simplex, all effective to antibacterial, mycete, infusorian, gonorrhea etc.Chlorhexidine (hibitane) is to integrate antibacterial, sterilization, anticorrosion medicine for external use.More superior than other simple property externally-applied female medicines.
Treatment vaginal bacteria such as clinical chlorhexidine commonly used (hibitane) suppository, washing liquid and fungal infection (as purulent vaginitis, colpitis mycotica, cervical erosion) also are used for the treatment of trichomonal vaginitis, have obtained clinical effectiveness preferably.Also useful chlorhexidine (hibitane) liniment treatment cervicitis also obtains satisfied curative effect.In addition, because of unsuitable vagina lavation of pregnancy period, unsuitable oral metronidazole and nystatin medicine can adopt chlorhexidine (hibitane) liquid topical therapeutic.Finding in the therapeutic process that this medicine can reduce patient leucorrhea amount, ease the pain and pruritus vulvae, is a kind of safe and reliable medicine.
Be used for the treatment of and prevent chlorhexidine (hibitane) the local application dosage form of gynecological inflammation existing a lot of at present, as solution, suppository, liniment etc.Comparatively speaking, solution uses inconvenient, and tack is poor, to such an extent as to influence therapeutic effect; And suppository, liniment patient's toleration is relatively poor, sometimes pollution clothes.And gel of the present invention solves these problems.
Summary of the invention
The present invention finds, gives chlorhexidine with the form of gel, can increase curative effect and patient's toleration.
Sterilizing gel of the present invention, it by chlorhexidine or its physiologically acceptable salt and the medicine acceptable carrier that is fit to make gel form.
Gel of the present invention, the physiologically acceptable salt of wherein said chlorhexidine is chlorhexidine acetate and chlorhexidine gluconate.
Gel of the present invention, wherein said carrier comprise filler, forming agent, synergist and pH regulator agent.
Gel of the present invention, wherein said forming agent is selected from one or more in tragakanta, gelatin, starch, cellulose derivative, carbopol and the sodium alginate, preferred cellulose derivant, most preferably hydroxyethyl-cellulose and hydroxypropyl methylcellulose.
The wherein said synergist of gel of the present invention is selected from ethanol, isopropyl alcohol, propylene glycol and pentanediol.Preferred alcohol, isopropyl alcohol, most preferred ethanol.
The wherein said pH regulator agent of gel of the present invention is selected from lactic acid, citric acid, tartaric acid, malic acid, succinic acid, 1,3-propanedicarboxylic acid, maleic acid, glutamic acid, mandelic acid, fumaric acid, one or more in the phosphoric acid.Preferred lactic acid, citric acid, most preferably lactic acid.
Gel of the present invention, preferably by chlorhexidine or its physiologically acceptable salt and hydroxyethyl-cellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxyethyl-cellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
Gel of the present invention, preferably by chlorhexidine or its physiologically acceptable salt and hydroxypropyl methylcellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxypropyl methylcellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
Gel of the present invention, more preferably, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.5-5% of total formulation weight amount, hydroxypropyl methylcellulose or hydroxyethyl-cellulose account for the 0.5-5% of total formulation weight amount, ethanol accounts for the 0.5-5% of total formulation weight amount, and lactic acid accounts for the 0.002-0.01% of total formulation weight amount.
The chlorhexidine physiologically acceptable salt also can be selected from hydrochlorate.Filler in the carrier is a water.
The present invention provides the method for preparing gel of the present invention simultaneously.It is the conventional preparation technology of gel: comprise chlorhexidine or its physiologically acceptable salt are added in the synergist by a certain percentage stirring and dissolving; Forming agent is added heated and stirred dissolving extremely fully in the purified water, be heated to about 85 ℃, be incubated about 30 minutes, stir, be cooled to about 60 ℃, add the pH regulator agent, adjust pH, stir, be cooled to about 45 ℃, add the chlorhexidine of preparation in advance or the synergist solution of its physiological acceptable salt, be cooled to about 35 ℃, stirred 30 minutes, and detected appearance transparent and do not have behind the granule.
Gel of the present invention can be used for treatment and prevention gynecological inflammation, as: various vaginitiss, pruritus vulvae, cervicitis etc.
Gel of the present invention, the preparation of particularly preferred prescription composition shows that through a large amount of experiments curative effect strengthens, side effect reduces, good stability, prescription is reasonable, and easy to use, technology is simple, and cost is low, has reached the best-of-breed technology effect.
The specific embodiment
Below in conjunction with specific embodiment the present invention is described in detail:
Embodiment 1:
Prescription:
Chlorhexidine acetate 200g
Hydroxyethyl-cellulose (HEC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95797g
Preparation technology:
Chlorhexidine acetate is added in the ethanol, after stirring and dissolving, place stand-by.
The HEC of recipe quantity is added in the purified water, and heated and stirred is dissolved fully to HEC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, adjust pH 5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine acetate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule, promptly.
Embodiment 2:
Prescription:
Chlorhexidine gluconate 300g
Hydroxypropyl methylcellulose (HPMC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95697g
Preparation technology:
Chlorhexidine gluconate is added in the ethanol, after stirring and dissolving, place stand-by.
The HPMC of recipe quantity is added in the purified water, and heated and stirred is dissolved fully to HPMC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, adjust pH 5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine gluconate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule, promptly.
Embodiment 3:
Prescription:
Chlorhexidine acetate 20g
Hydroxyethyl-cellulose (HEC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95977g
Preparation technology:
Chlorhexidine acetate is added in the ethanol, after stirring and dissolving, place stand-by.
The HEC of recipe quantity is added purified water, and heated and stirred is dissolved fully to HEC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, adjust pH 5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine acetate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule.Promptly get gel of the present invention.
Embodiment 4:
Prescription:
Chlorhexidine gluconate 900g
Hydroxyethyl-cellulose (HEC) 2000g
Ethanol (95%) 2000g
Lactic acid (left-handed) 3g
Water 95097g
Preparation technology:
Chlorhexidine gluconate is added in 95% ethanol, after stirring and dissolving, place stand-by.
The HEC of recipe quantity is added in the purified water, and heated and stirred is dissolved fully to HEC, is heated to 85 ℃, is incubated 30 minutes.Stir, be cooled to 60 ℃, add lactic acid, tone pitch pH5.0-7.0 with 10 times of water gaging dilutions; Stir, be cooled to 45 ℃, add the chlorhexidine gluconate alcoholic solution of preparation in advance, be cooled to 35 ℃, stirred 30 minutes, the detection appearance transparent does not have discharging behind the granule, promptly.
Embodiment 5:
Stability test 1
Get packaged sample, earlier-5 ℃ of storages 24 hours, take out recover room temperature after, put into 40 ℃ of constant temperature ovens storages 24 hours again, continuous like this carry out three heat-resisting cold-resistant circulations after, recover room temperature.In forward and backward outward appearance, color and luster, fragrance, pH value and the viscosity of detecting respectively of circulation.
Evaluation result before and after table 1 circulation
Evaluation result appearance luster fragrance pH value viscosity (cps)
Gel water white transparency free from extraneous odour 6.2 39000 before the circulation
Circulation back gel water white transparency no change 6.1 38500
The product physical and chemical index did not have significant change, requirement up to specification before and after the result showed circulation.
Stability test 2
Get the good sample of embodiment 1 intermediate package, place in 54 ℃ of calorstats.Use the content of determined by ultraviolet spectrophotometry chlorhexidine respectively at (0 day), placement before placing after 14 days and 30 days.Measurement result is as showing:
Table 2 chlorhexidine stability test result
Place after 14 days before placing and place after 30 days
0.0987％ 0.0982％ 0.0981％
The result shows that placing the front and back chlorhexidine acetate does not have significant change, requirement up to specification.
Above-mentioned explanation, embodiment and data provide the complete preparation and the purposes of gel of the present invention.Because many specific embodiments are not being violated under character of the present invention and the scope situation and can accomplished, they also should be included in the claim scope of the present invention.
Claims (10)
1. sterilizing gel, it by chlorhexidine or its physiologically acceptable salt and the medicine acceptable carrier that is fit to make gel form.
2. the gel in the claim 1, the physiologically acceptable salt of wherein said chlorhexidine is chlorhexidine acetate and chlorhexidine gluconate.
3. the gel in the claim 1, wherein said carrier comprises forming agent, synergist and pH regulator agent.
4. the gel in the claim 3, wherein said forming agent is selected from one or more in tragakanta, gelatin, starch, cellulose derivative, carbopol and the sodium alginate.
5. the gel in the claim 3, wherein said synergist is selected from ethanol, isopropyl alcohol, propylene glycol and pentanediol.
6. the gel in the claim 3, wherein said pH regulator agent is selected from lactic acid, citric acid, tartaric acid, malic acid, succinic acid, 1,3-propanedicarboxylic acid, maleic acid, glutamic acid, mandelic acid, fumaric acid, one or more in the phosphoric acid.
7. the gel in the claim 4, wherein said cellulose derivative is selected from hydroxyethyl-cellulose, hydroxypropyl methylcellulose.
8. the gel in the claim 1, by chlorhexidine or its physiologically acceptable salt and hydroxyethyl-cellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxyethyl-cellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
9. the gel in the claim 1, by chlorhexidine or its physiologically acceptable salt and hydroxypropyl methylcellulose, ethanol, lactic acid is formed, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.01%-5% of total formulation weight amount, and hydroxypropyl methylcellulose accounts for the 0.2%-20% of total formulation weight amount, ethanol accounts for the 0.2-20% of total formulation weight amount, and lactic acid accounts for the 0.001-0.1% of total formulation weight amount.
10. the gel in the claim 8 or 9, wherein, chlorhexidine or its physiologically acceptable salt account for the 0.5-5% of total formulation weight amount, hydroxypropyl methylcellulose or hydroxyethyl-cellulose account for the 0.5-5% of total formulation weight amount, ethanol accounts for the 0.5-5% of total formulation weight amount, and lactic acid accounts for the 0.002-0.01% of total formulation weight amount.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100539041A CN1301106C (en) | 2005-03-11 | 2005-03-11 | Sterilizing gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100539041A CN1301106C (en) | 2005-03-11 | 2005-03-11 | Sterilizing gel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682703A true CN1682703A (en) | 2005-10-19 |
| CN1301106C CN1301106C (en) | 2007-02-21 |
Family
ID=35262324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100539041A Expired - Fee Related CN1301106C (en) | 2005-03-11 | 2005-03-11 | Sterilizing gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301106C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101310702B (en) * | 2007-05-25 | 2011-10-26 | 上海利康消毒高科技有限公司 | Emulsion type gel preparation containing chlorhexidine and alcohol |
| CN103463140A (en) * | 2013-09-22 | 2013-12-25 | 汤永强 | Disinfection repairing liquid |
| CN109692128A (en) * | 2018-12-20 | 2019-04-30 | 扬州倍加洁日化有限公司 | A kind of antibacterial wet tissue and its production method |
| CN106176398B (en) * | 2016-08-18 | 2019-11-19 | 吉安市御美丽健康产业股份有限公司 | A kind of women repairs the preparation method of liquid |
| CN111434334A (en) * | 2019-01-11 | 2020-07-21 | 李可 | Female gel |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3376957D1 (en) * | 1982-06-24 | 1988-07-14 | Robert Alan Smith | Pharmaceutical gel composition |
| JP2533723B2 (en) * | 1992-12-28 | 1996-09-11 | 東興薬品工業株式会社 | Quick-drying gel type hand sanitizer |
| CN1077373A (en) * | 1993-04-06 | 1993-10-20 | 王师舜 | Sex emollient disinfectant |
| CN1090205A (en) * | 1993-09-01 | 1994-08-03 | 林亚萍 | The preparation method of aquogel with polyvinyl alcohol support and product |
| GB9408545D0 (en) * | 1994-04-29 | 1994-06-22 | Zyma Sa | Compositions |
-
2005
- 2005-03-11 CN CNB2005100539041A patent/CN1301106C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101310702B (en) * | 2007-05-25 | 2011-10-26 | 上海利康消毒高科技有限公司 | Emulsion type gel preparation containing chlorhexidine and alcohol |
| CN103463140A (en) * | 2013-09-22 | 2013-12-25 | 汤永强 | Disinfection repairing liquid |
| CN106176398B (en) * | 2016-08-18 | 2019-11-19 | 吉安市御美丽健康产业股份有限公司 | A kind of women repairs the preparation method of liquid |
| CN109692128A (en) * | 2018-12-20 | 2019-04-30 | 扬州倍加洁日化有限公司 | A kind of antibacterial wet tissue and its production method |
| CN111434334A (en) * | 2019-01-11 | 2020-07-21 | 李可 | Female gel |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1301106C (en) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3520785B1 (en) | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use | |
| US6440949B1 (en) | Method for promoting the growth of gram-positive bacilli and increasing the acidity in vagina | |
| JP2005511642A5 (en) | ||
| CN1301106C (en) | Sterilizing gel | |
| CN100457084C (en) | Nanometer silver type external use antibiotic gel for female external use and its prepn. method | |
| AU2005257722A1 (en) | Composition comprising lactic acid and lactoferrin | |
| CN105126107A (en) | Liquid wound dressing | |
| CN102028705A (en) | Gynecologic article containing biological antifungal components | |
| CN1823813A (en) | Nursing and treating composition for female vagina and its preparation method | |
| CN108420789A (en) | A kind of benzalkonium chloride externally used solution and preparation method thereof | |
| CN110743003A (en) | anti-HPV type vaginal temperature-sensitive gel, preparation method and application thereof | |
| CN102048729B (en) | Preparation for treating vaginitis | |
| CN104069124A (en) | Composition and preparation for gynecologic infections | |
| CN107811964A (en) | Antibacterial conception control gel that is biodegradable and realizing dosed administration | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN102000092B (en) | New application of sulfadiazine sodium in preparing medicine for preventing or treating Bombyx mori septicemia | |
| CN101766813A (en) | Suppository for treating mammalian endometritis and preparation method thereof | |
| CN1911441A (en) | Lysostaphin freeze dried powder used for preventing and treating cattle edometritis | |
| CN111329846A (en) | Vaginal sterilization adhesive film and preparation method thereof | |
| WO2017193509A1 (en) | Bionic gynecological lotion and preparation method therefor | |
| CN101797374A (en) | Compound minocycline hydrochloride soluble powder for treating respiratory diseases of poultry | |
| CN111588773B (en) | Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof | |
| CN106974926B (en) | A kind of pharmaceutical composition and its preparation method and application for treating pressure sore | |
| CN1297563C (en) | Clindamycin and metronidazole pessary | |
| CN108096182A (en) | Gynecological antibacterial gel based on green antibacterial material and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070221 Termination date: 20100311 |